GO:0045602 negative regulation of endothelial cell differentiation: Signaling Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045602 describes any process that stops, prevents, or reduces the frequency, rate, or extent of endothelial cell differentiation.
• VEGF and Notch signaling are central regulators of endothelial cell differentiation and arterial specification, and their inhibition can block endothelial differentiation programs.
• Cytokines such as VEGFC, VEGFD, and angiopoietins regulate lymphangiogenesis, a process closely related to endothelial cell differentiation.
• EPH receptor A4 (EPHA4) deletion in endothelial cells alters single-cell profiles and Tie2/Akap12 signaling, preserving blood-brain barrier integrity.
• SIRT1 negatively regulates NLRP3 inflammasome in vascular endothelial cells, linking metabolic and inflammatory signaling to endothelial cell state.
• Exosomal DMBT1 from urine-derived stem cells promotes angiogenesis, highlighting extracellular cues that can override negative regulation of endothelial differentiation.
Description
Endothelial cell differentiation is the process by which progenitor cells acquire the specialized characteristics of endothelial cells, which line the interior surface of blood and lymphatic vessels. This process is essential for vascular development, angiogenesis, and tissue homeostasis. However, uncontrolled or aberrant endothelial differentiation contributes to pathological conditions such as tumor angiogenesis, diabetic retinopathy, and inflammatory vascular diseases. Therefore, negative regulation of endothelial cell differentiation (GO:0045602) serves as a critical brake that maintains vascular quiescence and prevents excessive or inappropriate vessel formation [3, 5]. Understanding the molecular mechanisms that inhibit endothelial differentiation is fundamental for developing therapies that modulate angiogenesis in cancer, wound healing, and cardiovascular disease [4, 6].
negative regulation of endothelial cell differentiation At A Glance
| GO ID | GO:0045602 |
|---|---|
| GO term | negative regulation of endothelial cell differentiation |
| Ontology | biological_process |
| Synonym | down regulation of endothelial cell differentiation, down-regulation of endothelial cell differentiation, downregulation of endothelial cell differentiation, inhibition of endothelial cell differentiation |
| Major function | Stops, prevents, or reduces the frequency, rate, or extent of endothelial cell differentiation |
| Related processes | Angiogenesis, lymphangiogenesis, arterial specification, vascular quiescence |
| Key signaling pathways | VEGF, Notch, Tie2/Akap12, SIRT1/NLRP3 |
| Disease relevance | Cancer, diabetic wound repair, blood-brain barrier integrity, inflammatory vascular disease |
What Is GO:0045602?
GO:0045602, negative regulation of endothelial cell differentiation, is defined as any biological process that stops, prevents, or reduces the frequency, rate, or extent of endothelial cell differentiation. This regulation can occur through cell-intrinsic mechanisms, such as transcriptional repression or signaling pathway inhibition, or through extracellular cues that block the transition of progenitor cells into mature endothelial cells [3, 5].
Why Is negative regulation of endothelial cell differentiation Important in Cell Biology?
Negative regulation of endothelial cell differentiation is essential for maintaining vascular homeostasis and preventing pathological angiogenesis. In tumors, excessive endothelial differentiation supports tumor growth and metastasis, while in chronic inflammatory diseases, uncontrolled endothelial activation contributes to vascular leakage and tissue damage. Understanding how this process is negatively regulated provides opportunities to develop anti-angiogenic therapies, promote vascular repair, and modulate immune cell interactions within the tumor microenvironment [2, 3, 5, 6, 8].
• Prevents excessive angiogenesis in tumors and metastatic niches [2, 7].
• Maintains blood-brain barrier integrity by regulating endothelial cell state.
• Modulates lymphangiogenesis through cytokine signaling.
• Controls inflammatory responses in vascular endothelial cells via SIRT1/NLRP3 axis.
• Influences diabetic wound repair by regulating angiogenesis.
• Regulates arterial specification through VEGF and Notch signaling.
• Impacts single-cell heterogeneity of endothelial cells in health and disease [1, 6].
• Provides therapeutic targets for anti-angiogenic cancer therapy [2, 7].
• Affects immune cell interactions in head and neck tumors.
• Plays a role in knee osteoarthritis pathogenesis through chondrocyte and osteoblast subtypes.
What Happens During negative regulation of endothelial cell differentiation?
Inhibition of VEGF signaling
In simple terms: Blocking the main growth signal that tells cells to become blood vessel cells.
VEGF signaling is a primary driver of endothelial cell differentiation and arterial specification. Negative regulation of this pathway can occur through soluble decoy receptors, microRNAs, or intracellular inhibitors that prevent VEGF receptor activation. Hirashima (2009) demonstrated that VEGF and Notch signaling coordinately regulate endothelial cell differentiation and arterial specification, and that inhibition of these pathways can suppress endothelial differentiation programs.
Notch-mediated repression
In simple terms: Notch signaling acts like a switch that can keep cells from becoming endothelial cells.
Notch signaling is a key negative regulator of endothelial cell differentiation. Activation of Notch receptors by Delta-like or Jagged ligands on neighboring cells leads to transcriptional repression of endothelial-specific genes, such as VEGFR2 and Tie2. This mechanism ensures proper arterial-venous specification and prevents excessive endothelial cell proliferation. Hirashima (2009) highlighted the interplay between VEGF and Notch in regulating endothelial cell differentiation and arterial specification.
Tie2/Akap12 signaling and EPH receptor A4
In simple terms: Specialized receptors on endothelial cells help keep blood vessels stable and prevent them from becoming leaky.
Endothelial deletion of EPH receptor A4 (EPHA4) alters single-cell profiles and Tie2/Akap12 signaling, leading to preserved blood-brain barrier integrity. This suggests that EPHA4 negatively regulates endothelial cell differentiation or activation states that compromise barrier function. Cash et al. (2023) showed that loss of EPHA4 in endothelial cells changes the single-cell landscape and enhances Tie2/Akap12 signaling, which is associated with a more quiescent endothelial phenotype.
SIRT1-mediated inhibition of NLRP3 inflammasome
In simple terms: A protein called SIRT1 reduces inflammation in blood vessel cells, which can prevent them from becoming overly activated.
SIRT1 negatively regulates the NLRP3 inflammasome in vascular endothelial cells. Li et al. (2017) demonstrated that SIRT1 inhibition increases NLRP3 inflammasome activation, leading to endothelial cell dysfunction and inflammation. This pathway represents a negative regulatory mechanism that maintains endothelial cell quiescence and prevents excessive differentiation or activation.
Cytokine regulation of lymphangiogenesis
In simple terms: Cytokines can either promote or block the formation of lymphatic vessels from endothelial cells.
Cytokines such as VEGFC, VEGFD, and angiopoietins regulate lymphangiogenesis, a specialized form of endothelial cell differentiation. Sáinz-Jaspeado and Betsholtz (2018) reviewed how cytokines can negatively regulate lymphangiogenesis by modulating VEGFR3 signaling and downstream pathways. This negative regulation is critical for preventing lymphatic hyperplasia and maintaining fluid homeostasis.
Exosomal DMBT1 and angiogenesis
In simple terms: Tiny vesicles released by stem cells can carry proteins that promote or inhibit blood vessel growth.
Exosomal DMBT1 from human urine-derived stem cells facilitates diabetic wound repair by promoting angiogenesis. Chen et al. (2018) showed that DMBT1-containing exosomes enhance endothelial cell proliferation and migration, suggesting that negative regulation of endothelial differentiation can be overcome by specific extracellular signals. This highlights the balance between positive and negative regulators in tissue repair.
Key Genes Involved in GO:0045602 negative regulation of endothelial cell differentiation
The following genes and proteins are key players in the negative regulation of endothelial cell differentiation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| VEGFA | Primary driver of endothelial differentiation; negative regulation blocks its signaling | Target for anti-angiogenic therapy |
| NOTCH1 | Transcriptionally represses endothelial genes; promotes arterial specification | Key negative regulator in vascular development |
| DLL4 | Notch ligand that activates Notch signaling in endothelial cells | Modulates angiogenesis and arterial differentiation |
| EPHA4 | Receptor tyrosine kinase; deletion alters Tie2/Akap12 signaling and preserves BBB | Regulates endothelial quiescence and barrier integrity |
| TIE2 | Endothelial receptor tyrosine kinase; activated by angiopoietins | Maintains vascular stability; downstream of EPHA4 |
| AKAP12 | Scaffolding protein that modulates Tie2 signaling | Involved in endothelial barrier function |
| SIRT1 | Deacetylase that inhibits NLRP3 inflammasome in endothelial cells | Negative regulator of endothelial inflammation |
| NLRP3 | Inflammasome component; activation promotes endothelial dysfunction | Target of SIRT1-mediated negative regulation |
| VEGFC | Lymphangiogenic cytokine; can negatively regulate lymphangiogenesis | Regulates lymphatic endothelial differentiation |
| VEGFD | Lymphangiogenic cytokine; modulates VEGFR3 signaling | Involved in lymphangiogenesis |
| ANGPT1 | Angiopoietin that stabilizes vessels and reduces endothelial activation | Negative regulator of endothelial differentiation |
| ANGPT2 | Angiopoietin that destabilizes vessels and promotes angiogenesis | Context-dependent regulator |
| DMBT1 | Exosomal protein that promotes angiogenesis in diabetic wound repair | Overcomes negative regulation of endothelial differentiation |
| CD31 | Endothelial cell adhesion molecule; marker of differentiated endothelial cells | Used to assess endothelial differentiation status |
| VWF | Von Willebrand factor; stored in endothelial Weibel-Palade bodies | Marker of mature endothelial cells |
| CDH5 | VE-cadherin; endothelial junctional protein | Maintains endothelial barrier and differentiation state |
| KDR | VEGFR2; receptor for VEGF; mediates endothelial differentiation | Target of negative regulation by Notch |
How Is negative regulation of endothelial cell differentiation Regulated?
Negative regulation of endothelial cell differentiation is controlled by a network of signaling pathways, including VEGF/Notch, Tie2/Akap12, and SIRT1/NLRP3. Notch signaling acts as a primary brake by repressing endothelial-specific genes such as KDR and TIE2. EPHA4 deletion alters Tie2/Akap12 signaling to preserve blood-brain barrier integrity, suggesting that EPHA4 negatively regulates endothelial activation states. SIRT1 inhibits NLRP3 inflammasome in vascular endothelial cells, providing a metabolic-inflammatory checkpoint. Cytokines such as VEGFC, VEGFD, and angiopoietins modulate lymphangiogenesis, a specialized endothelial differentiation process. These pathways are tightly regulated to maintain vascular quiescence and prevent pathological angiogenesis.
negative regulation of endothelial cell differentiation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EPHA4 | Blood-brain barrier integrity | Endothelial-specific knockout mouse |
| SIRT1 | Inflammatory vascular disease | SIRT1 knockout or overexpression in endothelial cells |
| DMBT1 | Diabetic wound repair | Exosome treatment in diabetic wound models |
| NOTCH1 | Cancer angiogenesis | Notch1 knockout or overexpression in endothelial cells |
| NLRP3 | Vascular inflammation | NLRP3 knockout mice |
Cancer and tumor angiogenesis
Negative regulation of endothelial cell differentiation is critical in cancer, where tumors secrete pro-angiogenic factors like VEGF to promote endothelial differentiation and vessel formation. Single-cell RNA sequencing of head and neck tumors revealed complex immune and non-immune cell interactions, including endothelial cells that support tumor growth. Palmitic acid reprograms neutrophils to compromise vascular integrity and promote breast cancer lung metastasis, highlighting how metabolic signals can override negative regulation of endothelial differentiation. Targeting negative regulators such as Notch or EPHA4 could provide therapeutic strategies to inhibit tumor angiogenesis [3, 6].
Blood-brain barrier integrity and neurological disease
Endothelial deletion of EPHA4 alters single-cell profile and Tie2/Akap12 signaling to preserve blood-brain barrier integrity. This suggests that negative regulation of endothelial cell differentiation is essential for maintaining the blood-brain barrier. Dysregulation of this process may contribute to neurological diseases characterized by barrier breakdown, such as multiple sclerosis or stroke. Modulating EPHA4 or Tie2 signaling could be a therapeutic approach to protect the blood-brain barrier.
Diabetic wound repair and vascular complications
Exosomal DMBT1 from human urine-derived stem cells facilitates diabetic wound repair by promoting angiogenesis. In diabetes, impaired angiogenesis contributes to poor wound healing. Negative regulation of endothelial cell differentiation may be overly active in diabetic tissues, and overcoming this brake with exosomal DMBT1 or other factors could improve wound repair. This highlights the therapeutic potential of targeting negative regulators of endothelial differentiation.
Inflammatory vascular disease and osteoarthritis
SIRT1 negatively regulates NLRP3 inflammasome in vascular endothelial cells, linking inflammation to endothelial dysfunction. In knee osteoarthritis, single-cell transcriptomics revealed novel chondrocyte and osteoblast subtypes and their role in pathogenesis. Although osteoarthritis is primarily a joint disease, vascular changes in subchondral bone may involve endothelial differentiation. Understanding negative regulation of endothelial differentiation in these contexts could reveal new therapeutic targets [1, 8].
From negative regulation of endothelial cell differentiation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate endothelial differentiation? | Knockout of gene X in endothelial cells followed by differentiation assays |
| Does a point mutation in gene X affect its function? | Point-mutation knock-in of the mutation in endothelial cells |
| Does overexpression of gene X inhibit endothelial differentiation? | Overexpression of gene X in endothelial progenitor cells |
| Does gene X interact with Tie2/Akap12 signaling? | Tagged knock-in of gene X for co-immunoprecipitation |
| Does gene X regulate blood-brain barrier integrity? | Endothelial-specific knockout mouse with BBB permeability assays |
| Does gene X modulate tumor angiogenesis? | Xenograft tumor models with endothelial-specific knockout |
How to Study the negative regulation of endothelial cell differentiation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| scRNA-seq | Single-cell transcriptomes | Identify endothelial subpopulations and differentiation states [1, 2, 6] |
| In vitro differentiation assay | Endothelial marker expression and tube formation | Test negative regulators of endothelial differentiation [3, 4] |
| Proteomics | Protein expression and signaling changes | Identify pathways altered by negative regulators |
| Phosphoproteomics | Phosphorylation events | Map signaling downstream of negative regulators |
| Immunofluorescence | Protein localization and morphology | Assess endothelial junctional integrity |
| Barrier function assay | Permeability to tracers | Measure blood-brain barrier integrity |
| Exosome isolation and treatment | Angiogenic potential of exosomes | Study DMBT1-mediated wound repair |
| Flow cytometry | Endothelial surface markers | Quantify differentiated endothelial cells |
Single-cell RNA sequencing
Single-cell RNA sequencing (scRNA-seq) allows researchers to profile endothelial cell heterogeneity and identify subpopulations undergoing differentiation or negative regulation. Liu et al. (2025) used scRNA-seq to reveal novel chondrocyte and osteoblast subtypes in knee osteoarthritis, demonstrating the power of this method to uncover cell states. Kürten et al. (2021) applied scRNA-seq to investigate immune and non-immune cell interactions in head and neck tumors, including endothelial cells. Cash et al. (2023) used scRNA-seq to show that endothelial deletion of EPHA4 alters single-cell profiles.
In vitro endothelial differentiation assays
In vitro assays using endothelial progenitor cells or induced pluripotent stem cells can measure the rate and extent of endothelial differentiation. These assays typically assess the expression of endothelial markers such as CD31, VWF, and CDH5, as well as functional properties like tube formation and acetylated LDL uptake. Negative regulators can be tested by knockout, knockdown, or overexpression followed by differentiation induction [3, 4].
Proteomics and phosphoproteomics
Proteomic approaches can identify changes in signaling pathways, such as Tie2/Akap12, upon modulation of negative regulators. Cash et al. (2023) used biochemical methods to show altered Tie2/Akap12 signaling upon EPHA4 deletion. Phosphoproteomics can reveal downstream phosphorylation events that mediate negative regulation of endothelial differentiation.
Imaging and barrier function assays
Imaging techniques such as immunofluorescence and live-cell microscopy can visualize endothelial cell morphology, junctional integrity, and barrier function. Blood-brain barrier integrity can be assessed using tracer leakage assays in vivo. Cash et al. (2023) used such methods to demonstrate preserved blood-brain barrier integrity upon endothelial EPHA4 deletion.
How CRISPR Can Be Used to Study GO:0045602 negative regulation of endothelial cell differentiation
Knockout
CRISPR knockout of candidate negative regulators, such as EPHA4 or SIRT1, in endothelial cells or mouse models can determine whether they are necessary for inhibiting endothelial differentiation. For example, endothelial-specific EPHA4 knockout alters single-cell profiles and Tie2/Akap12 signaling. SIRT1 knockout increases NLRP3 inflammasome activation in vascular endothelial cells.
Point Mutation
CRISPR point mutation can introduce specific amino acid changes to dissect domain functions of negative regulators. For instance, mutating phosphorylation sites in Tie2 or Akap12 can reveal their role in endothelial barrier maintenance. Point mutations in Notch1 can affect its transcriptional repression activity.
Knock-in
CRISPR knock-in of tagged versions of negative regulators, such as GFP-EPHA4 or HA-Akap12, allows for localization and interaction studies. Knock-in of reporter genes under endothelial-specific promoters can track differentiation states in vivo.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can drive high levels of negative regulators to test whether they are sufficient to block endothelial differentiation. Overexpression of DMBT1 in exosomes promotes angiogenesis, suggesting that overcoming negative regulation can enhance repair. Overexpression of SIRT1 inhibits NLRP3 inflammasome in endothelial cells.
How EDITGENE Supports negative regulation of endothelial cell differentiation Research
Researchers studying negative regulation of endothelial cell differentiation-related genes often need to determine whether a candidate gene is causally involved in inhibiting endothelial differentiation, and whether specific mutations alter its function. EDITGENE provides comprehensive CRISPR-based services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of endothelial cell differentiation research.
Frequently Asked Questions About negative regulation of endothelial cell differentiation
What is GO:0045602?
GO:0045602 is the Gene Ontology term for negative regulation of endothelial cell differentiation, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of endothelial cell differentiation.
What genes are involved in negative regulation of endothelial cell differentiation?
Key genes include NOTCH1, DLL4, EPHA4, TIE2, AKAP12, SIRT1, NLRP3, VEGFC, VEGFD, ANGPT1, and ANGPT2 [3, 5, 6, 8].
How does Notch signaling negatively regulate endothelial differentiation?
Notch signaling represses endothelial-specific genes such as KDR and TIE2, thereby inhibiting endothelial differentiation and promoting arterial specification.
What is the role of EPHA4 in endothelial cells?
Endothelial deletion of EPHA4 alters single-cell profiles and Tie2/Akap12 signaling to preserve blood-brain barrier integrity, suggesting EPHA4 negatively regulates endothelial activation.
How does SIRT1 regulate endothelial inflammation?
SIRT1 negatively regulates the NLRP3 inflammasome in vascular endothelial cells, reducing inflammation and maintaining endothelial quiescence.
What diseases are associated with dysregulated endothelial differentiation?
Cancer, diabetic wound repair, blood-brain barrier breakdown, inflammatory vascular disease, and osteoarthritis [1, 2, 4, 6, 7, 8].
What methods are used to study negative regulation of endothelial differentiation?
Single-cell RNA sequencing, in vitro differentiation assays, proteomics, phosphoproteomics, imaging, and CRISPR screens [1, 2, 3, 4, 6].
How can CRISPR be used to study this process?
CRISPR knockout, point mutation, knock-in, and overexpression can test the causal role of candidate genes in inhibiting endothelial differentiation [3, 4, 6, 8].
What is the role of cytokines in lymphangiogenesis?
Cytokines such as VEGFC, VEGFD, and angiopoietins regulate lymphangiogenesis, a specialized form of endothelial differentiation, and can negatively regulate it.
Why is negative regulation of endothelial differentiation important for cancer therapy?
Tumors rely on endothelial differentiation for angiogenesis; targeting negative regulators can inhibit tumor vessel formation and metastasis [2, 7].
Conclusion
Negative regulation of endothelial cell differentiation (GO:0045602) is a critical biological process that maintains vascular homeostasis and prevents pathological angiogenesis. Key signaling pathways, including VEGF/Notch, Tie2/Akap12, and SIRT1/NLRP3, orchestrate this regulation. Dysregulation of these pathways contributes to cancer, diabetic wound repair, blood-brain barrier breakdown, and inflammatory vascular disease. Advances in single-cell transcriptomics and CRISPR-based models are accelerating our understanding of these mechanisms and enabling the development of targeted therapies.
References
- 1. Liu Y et al.. 2025. Single-cell transcriptomics reveals novel chondrocyte and osteoblast subtypes and their role in knee osteoarthritis pathogenesis.. Signal Transduct Target Ther 10(1):40 PMID: 39904988
- 2. Kürten CHL et al.. 2021. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing.. Nat Commun 12(1):7338 PMID: 34921143
- 3. Hirashima M. 2009. Regulation of endothelial cell differentiation and arterial specification by VEGF and Notch signaling.. Anat Sci Int 84(3):95-101 PMID: 19259767
- 4. Chen CY et al.. 2018. Exosomal DMBT1 from human urine-derived stem cells facilitates diabetic wound repair by promoting angiogenesis.. Theranostics 8(6):1607-1623 PMID: 29556344
- 5. Sáinz-Jaspeado M et al.. 2018. Cytokines regulating lymphangiogenesis.. Curr Opin Immunol 53:58-63 PMID: 29680577
- 6. Cash A et al.. 2023. Endothelial deletion of EPH receptor A4 alters single-cell profile and Tie2/Akap12 signaling to preserve blood-brain barrier integrity.. Proc Natl Acad Sci U S A 120(41):e2204700120 PMID: 37796990
- 7. Qian P et al.. 2026. Palmitic acid reprograms neutrophils to compromise vascular integrity and promote breast cancer lung metastasis.. Immunity 59(7):1964-1981.e9 PMID: 42034064
- 8. Li Y et al.. 2017. Negative regulation of NLRP3 inflammasome by SIRT1 in vascular endothelial cells.. Immunobiology 222(3):552-561 PMID: 27908642
